<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37164">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622724</url>
  </required_header>
  <id_info>
    <org_study_id>FPCLI002</org_study_id>
    <nct_id>NCT02622724</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)</brief_title>
  <acronym>INTEREST</acronym>
  <official_title>A Phase III Double-blind, Randomised, Parallel-Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human IFN Beta-1a) and Placebo in the Treatment of Patients With Moderate or Severe Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faron Pharmaceuticals Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Faron Pharmaceuticals Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study effectiveness and safety of a new drug FP-1201-lyo (recombinant human
      interferon beta-1a) is compared to placebo. Investigation is conducted with patients who
      have acute respiratory distress syndrome (ARDS). The new drug is expected to reduce the time
      which a patient need to be on the ventilator and improve patient's chances of survival.
      Currently there are no approved drugs for treating moderate or severe ARDS patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III clinical study to investigate the efficacy and safety of FP-1201-lyo
      (recombinant human interferon [IFN] beta-1a) compared to placebo in patients diagnosed with
      moderate or severe acute respiratory distress syndrome (ARDS). Primary objective is to
      demonstrate the efficacy of FP-1201-lyo in improving the clinical course and outcome based
      on survival and need for mechanical ventilation. Currently there are no approved drugs for
      treating moderate or severe ARDS patients.

      FP-1201-lyo is a lyophilised powder form of recombinant human IFN beta-1a reconstituted in
      water for injection and is administered intravenously.

      Recombinant human IFN beta-1a is an approved treatment for patients for other indication and
      its safety profile in such patients is well characterised.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Endpoint: Any cause death</measure>
    <time_frame>Day 28</time_frame>
    <description>Primary Efficacy Endpoint: Composite endpoint including any cause death at D28</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy Endpoint: Days free of mechanical ventilation</measure>
    <time_frame>Day 28</time_frame>
    <description>Primary Efficacy Endpoint: Composite endpoint including days free of mechanical ventilation (VFDsurv) within 28 days among survivors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Safety: Adverse events and all deaths</measure>
    <time_frame>Up to Day 28, after Day 28 and up to Day 360</time_frame>
    <description>Adverse events [AE] up to D28, AEs occurring after D28 if the investigator considers there is a causal relationship with the study drug and all deaths up to D360</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint: All-cause mortality</measure>
    <time_frame>At Day 28, Day 90 and Day 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint: Mortality in ICU</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint: Mortality in hospital</measure>
    <time_frame>Up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other secondary efficacy endpoints: Days free of organ failure</measure>
    <time_frame>Day 28</time_frame>
    <description>Sequential Organ Failure Assessment methodology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other secondary efficacy endpoints: Days free of renal support</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other secondary efficacy endpoints: Days free of vasoactive support</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other secondary efficacy endpoints: Days free of mechanical ventilation</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other secondary efficacy endpoints: Number of ICU-free days</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other secondary efficacy endpoints: Number of days in hospital</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint: Presence of neutralising antibodies to IFN beta-1a</measure>
    <time_frame>Baseline and Day 28 (or last day in intensive care unit [ICU] or at withdrawal, if earlier)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint: Evaluation of pharmacodynamic [PD] using Myxovirus resistance protein A [MxA] biomarker</measure>
    <time_frame>From baseline to Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term efficacy endpoints relating to Quality of Life [Qol]</measure>
    <time_frame>Day 180</time_frame>
    <description>EuroQol 5-Dimensions 3-Levels questionnaire [EQ-5D-3L]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term efficacy endpoints relating to respiratory functioning</measure>
    <time_frame>Day 180</time_frame>
    <description>Forced expiratory volume in 1 second [FEV1]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term efficacy endpoints relating to neurological functioning</measure>
    <time_frame>Day 180</time_frame>
    <description>6-minute walk test [6MWT]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Safety: Physical examination</measure>
    <time_frame>From baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Safety: Vital signs</measure>
    <time_frame>From baseline to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Safety: Laboratory results</measure>
    <time_frame>From baseline to Day 28</time_frame>
    <description>Biochemistry, haematology and urinalysis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of Pharmacoeconomics: Days free of organ failure</measure>
    <time_frame>Day 28</time_frame>
    <description>Pharmacoeconomic evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Pharmacoeconomics: Days free of renal support</measure>
    <time_frame>Day 28</time_frame>
    <description>Pharmacoeconomic evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Pharmacoeconomics: Days free of vasoactive support</measure>
    <time_frame>Day 28</time_frame>
    <description>Pharmacoeconomic evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Pharmacoeconomics: Days free of mechanical ventilation</measure>
    <time_frame>Day 28</time_frame>
    <description>Pharmacoeconomic evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Pharmacoeconomics: Number of ICU-free days</measure>
    <time_frame>Day 28</time_frame>
    <description>Pharmacoeconomic evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Pharmacoeconomics: Number of days in hospital</measure>
    <time_frame>Day 28</time_frame>
    <description>Pharmacoeconomic evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Exploratory Variables relating to efficacy: Composite mortality and days free of mechanical ventilation</measure>
    <time_frame>Within 90 days</time_frame>
    <description>Composite endpoint including mortality and days free of mechanical ventilation (VFDsurv) among survivors</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Exploratory Variables relating to efficacy: Ordered categorical endpoint defined as improvement, no change or worsening in terms of gas exchange</measure>
    <time_frame>From baseline to Day 28</time_frame>
    <description>Ordered categorical endpoint defined as improvement, no change or worsening in terms of gas exchange (Partial pressure of oxygen [PaO2]/ Fraction of inspired oxygen [FiO2 ratio])</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the treatment-specific exploratory biomarker Cluster of differentiation 73 [CD73] concentration</measure>
    <time_frame>From baseline to Day 14</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in levels of potential inflammatory markers [PIMs], including but not limited to, interleukin-6 and -8</measure>
    <time_frame>From baseline to Day 14</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>A blood sample will be taken for pharmacogenetic analysis and correlation with other markers of the activity of FP-1201-lyo</measure>
    <time_frame>From baseline to Day 28</time_frame>
    <description>Any time patient is in the ICU</description>
  </other_outcome>
  <other_outcome>
    <measure>Extended long-term follow-up: 12-month mortality rate</measure>
    <time_frame>Day 360</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Extended long-term follow-up: Quality of Life</measure>
    <time_frame>Day 360</time_frame>
    <description>EuroQol 5-Dimensions 3-Levels questionnaire [EQ-5D-3L]</description>
  </other_outcome>
  <other_outcome>
    <measure>Extended long-term follow-up: Neurological functioning</measure>
    <time_frame>Day 360</time_frame>
    <description>6MWT</description>
  </other_outcome>
  <other_outcome>
    <measure>Extended long-term follow-up: Respiratory functioning</measure>
    <time_frame>Day 360</time_frame>
    <description>FEV1</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <arm_group>
    <arm_group_label>FP-1201-lyo 10 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FP-1201-lyo 10 μg (Interferon beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.
Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FP-1201-lyo Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.
Investigational placebo product is lyophilisate for solution for injection which will be reconstituted in water for injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1a</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>FP-1201-lyo 10 μg</arm_group_label>
    <other_name>FP-1201-lyo</other_name>
    <other_name>Traumakine</other_name>
    <other_name>ATC code L03AB07</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for investigational drug</description>
    <arm_group_label>FP-1201-lyo Placebo</arm_group_label>
    <other_name>FP-1201-lyo Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has a diagnosis of moderate or severe ARDS according to the Berlin definition
             of ARDS:

               -  Acute onset of respiratory failure within 1 week of a known clinical insult or
                  new or worsening respiratory symptoms

               -  Respiratory failure associated with known ARDS risk factors and not fully
                  explained by either cardiac failure or fluid overload (an objective assessment
                  of cardiac failure or fluid overload is needed if no risk factors for ARDS
                  [moderate or severe ARDS] are present)

               -  Radiological abnormalities on chest X-ray or on computerised tomography scan,
                  i.e., bilateral opacities that are not fully explained by effusions, nodules,
                  masses or lobar/lung collapse

               -  Hypoxaemia:

                    -  Moderate ARDS: PaO2/FiO2 &gt;100 mmHg (&gt;13.3 kPa) to ≤200 mmHg (≤26.6 kPa)
                       with positive end expiratory pressure (PEEP) ≥5 cmH2O

                    -  Severe ARDS: PaO2/FiO2 ≤100 mmHg (≤13.3 kPa) with positive end expiratory
                       pressure [PEEP] ≥5 centimeter of water [cmH2O]

          2. The radiological and hypoxaemia criteria (1.3 and 1.4) must be met within the same
             24-hour period. The time of onset of ARDS is when the last of the two specified ARDS
             criteria is met

          3. Administration of the first dose of study drug must be planned to take place within
             48 hours of first fulfilling the above inclusion criteria

          4. Patient is intubated and mechanically ventilated

          5. A signed informed consent form from the patient or the patient's personal legal
             representative or a professional legal representative must be available

          6. Patient is aged ≥18 years

        Exclusion Criteria:

          1. Woman known to be pregnant, lactating or with a positive (urine or serum test) or
             indeterminate (serum test) pregnancy test

          2. Patient is simultaneously taking part in another pharmacotherapy protocol

          3. Patient is not expected to survive for 24 hours

          4. Patient has an underlying clinical condition where, in the opinion of the
             Investigator, it would be extremely unlikely that the patient would come off
             ventilation, e.g., motor neurone disease, Duchenne muscular dystrophy or rapidly
             progressive interstitial pulmonary fibrosis

          5. Patient has severe chronic obstructive pulmonary disease requiring long-term home
             oxygen therapy or mechanical ventilation (non-invasive ventilation or via
             tracheotomy) except for continuous positive airway pressure (CPAP) or bi-level
             positive airway pressure used solely for sleep-disordered breathing

          6. Patient has congestive heart failure, defined as New York Heart Association class IV

          7. Patient has acute left ventricular failure

          8. Patient has liver failure (Child-Pugh grade C)

          9. Patient has received any prior interferon

         10. Patient has known hypersensitivity to natural or recombinant IFN beta or to any of
             the excipients

         11. Patient is receiving renal dialysis therapy for chronic renal failure

         12. Patient is receiving extra-corporeal membrane oxygenation, high-frequency oscillatory
             ventilation or any form of extra-corporeal lung support

         13. Patient has had any form of mechanical ventilation (invasive or non-invasive,
             excluding CPAP alone) for longer than 48 hours prior to the diagnosis of ARDS.
             Non-invasive ventilation has to be continuously applied for at least 12 hours per day
             in these 48 hours

         14. Patient has burns to ≥15% of their total body surface area
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey Bellingan, MD</last_name>
    <role>Study Director</role>
    <affiliation>University College London Hospitals, NHS, London, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>V Marco Ranieri, Prof. MD</last_name>
    <role>Study Director</role>
    <affiliation>Universita La Sapeinza Policlinico Umberto I, Rome, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilse Piippo, MD</last_name>
    <phone>+358 400 277 407</phone>
    <email>ilse.piippo@faronpharmaceuticals.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erasmus Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>B-1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Charleroi Site Hôpital Civil Marie Curie</name>
      <address>
        <city>Lodelinsart</city>
        <zip>B-6042</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Dinant Godinne UCL Namur</name>
      <address>
        <city>Yvoir</city>
        <zip>B-5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FI-00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>FI-70210</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>FI-33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional d'Orléans</name>
      <address>
        <city>Orléans</city>
        <state>Loiret</state>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU D'Angers</name>
      <address>
        <city>Angers</city>
        <state>Pays-de-la-Loire</state>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU De Poitiers</name>
      <address>
        <city>Poitiers</city>
        <state>Poitou-Charentes</state>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <state>Rhône</state>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles-Nicolle</name>
      <address>
        <city>Rouen</city>
        <state>Seine-Maritime</state>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Chemin des Bourrely</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bicêtre</name>
      <address>
        <city>Bicetre</city>
        <state>Île-de-France</state>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin, Réanimation Médicale Hospitalisation</name>
      <address>
        <city>Paris</city>
        <state>Île-de-France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg Klinik für Anästhesiologie</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn Klinik und Poliklinik für Anästhesiologie</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Klinik für Anästhesiologie und Intensivmedizin</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen Klinik für Anästhesiologie</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf Klinik für Intesivmedizin</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln Klinikum Merheim</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Leipzig Klinik und Poliklinik für Anäesthesiologie und Intensivtherapie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università degli Studi Milano Bicocca</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Maggiore</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Roma &quot;La Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <zip>00185</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario del Henares</name>
      <address>
        <city>Coslada</city>
        <zip>28822</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria Dr Negrin</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Mútua de Terrassa</name>
      <address>
        <city>Terrasa</city>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Rio Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital / Portsmouth Hospitals NHS Trust</name>
      <address>
        <city>Portsmouth</city>
        <state>Hampshire</state>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Infirmary University Hospitals, Bristol Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital, University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Hampshire</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals, NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St George's University Hospitals, NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital Imperial College Healthcre NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital St Mary's Hospital, Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W21NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 2, 2016</lastchanged_date>
  <firstreceived_date>November 24, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARDS, human</keyword>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>Respiratory Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
